Osteoporotic fractures
Conditions
Interventions
Low risk group of fracture:Active health/bone health basic supplements (calcium and vitamin D)/TCM treatment
High risk group of fracture:Oral alendronate therapy/oral risephosphate therapy/denosumab therapy/intravenous bisphosphonate therapy
Very high risk group of fracture:Teriparatide sequential oral alendronate sodium treatment/teriparatide sequential oral risephosphate sodium treatment/teriparatide sequential oral denosumab treatment/
Sponsors
The Second XiangYa Hospital, Central South University
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =50 years old; 2. DXA results met the diagnostic criteria of osteopenia or osteoporosis; 3. no previous effective anti-osteoporosis treatment; 4. no definite diseases leading to secondary osteoporosis; 5. Signed informed consent and volunteered to participate in the study;
Exclusion criteria
Exclusion criteria: 1. Patients received bisphosphonates, denosumab, teriparatide and other potent anti-osteoporosis drugs in the past 2 years; 2. Severe liver and kidney dysfunction, tumor; 3. The use of anti-osteoporosis drugs in this study is clearly contraindicated; 4. Use of drugs affecting bone metabolism for more than 3 months in the past year;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| New fragility fracture;Bone mineral density; | — |
Secondary
| Measure | Time frame |
|---|---|
| ß-CTX;P1NP;ALP;Radiographs of the skeleton;TBS;Bone microstructure;iPTH;25(OH)D;Blood routine;Hepatorenal function;Quality of Life scale score; | — |
Countries
China
Contacts
Public ContactZhongjian Xie
The Second XiangYa Hospital, Central South University
Outcome results
None listed